Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma

NCT00518206 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: NY-ESO-1 ISCOMATRIX® vaccine
DRUG: Cyclophosphamide

Sponsor

Ludwig Institute for Cancer Research

Collaborators

[object Object]
[object Object]